<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE ichicsr SYSTEM "http://eudravigilance.ema.europa.eu/dtd/icsr21xml.dtd">
<ichicsr lang="en">
	<ichicsrmessageheader>
		<messagetype>ichicsr</messagetype>
		<messageformatversion>2.1</messageformatversion>
		<messageformatrelease>2.0</messageformatrelease>
		<messagenumb>864732_123</messagenumb>
		<messagesenderidentifier>AMGENSAFETY</messagesenderidentifier>
		<messagereceiveridentifier>ZZFDA</messagereceiveridentifier>
		<messagedateformat>204</messagedateformat>
		<messagedate>20130125152705</messagedate>
	</ichicsrmessageheader>
	<safetyreport>
		<safetyreportversion>3</safetyreportversion>
		<safetyreportid>FR-AMGEN-FRACT2012079442</safetyreportid>
		<primarysourcecountry>FR</primarysourcecountry>
		<occurcountry>FR</occurcountry>
		<transmissiondateformat>102</transmissiondateformat>
		<transmissiondate>20130125</transmissiondate>
		<reporttype>2</reporttype>
		<serious>1</serious>
		<seriousnessdeath>2</seriousnessdeath>
		<seriousnesslifethreatening>2</seriousnesslifethreatening>
		<seriousnesshospitalization>1</seriousnesshospitalization>
		<seriousnessdisabling>2</seriousnessdisabling>
		<seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
		<seriousnessother>2</seriousnessother>
		<receivedateformat>102</receivedateformat>
		<receivedate>20121206</receivedate>
		<receiptdateformat>102</receiptdateformat>
		<receiptdate>20130123</receiptdate>
		<additionaldocument>2</additionaldocument>
		<fulfillexpeditecriteria>1</fulfillexpeditecriteria>
		<companynumb>FR-AMGEN-FRACT2012079442</companynumb>
		<primarysource>
			<reporterfamilyname>PRIVACY</reporterfamilyname>
			<reportercountry>FR</reportercountry>
			<qualification>1</qualification>
			<studyname>Unknown</studyname>
			<sponsorstudynumb>panitumumab study</sponsorstudynumb>
			<observestudytype>1</observestudytype>
		</primarysource>
		<sender>
			<sendertype>1</sendertype>
			<senderorganization>AMGENSAFETY</senderorganization>
			<senderdepartment>Amgen Global Safety</senderdepartment>
			<sendergivename>Paul</sendergivename>
			<senderfamilyname>Eisenberg</senderfamilyname>
			<senderstreetaddress>One Amgen Center Drive</senderstreetaddress>
			<sendercity>Thousand Oaks</sendercity>
			<senderstate>California</senderstate>
			<senderpostcode>91320</senderpostcode>
			<sendercountrycode>US</sendercountrycode>
			<sendertel>8054471000</sendertel>
			<sendertelcountrycode>1</sendertelcountrycode>
			<senderfax>8054994495</senderfax>
			<senderfaxcountrycode>1</senderfaxcountrycode>
			<senderemailaddress>dsstriage@amgen.com</senderemailaddress>
		</sender>
		<receiver>
			<receivertype>2</receivertype>
			<receiverorganization>ZZFDA</receiverorganization>
			<receivergivename>Bill</receivergivename>
			<receiverfamilyname>Taylor</receiverfamilyname>
			<receivercountrycode>US</receivercountrycode>
			<receiveremailaddress>wtaylor@oc.fda.gov</receiveremailaddress>
		</receiver>
		<patient>
			<patientinitial>PRIVACY</patientinitial>
			<patientbirthdateformat>102</patientbirthdateformat>
			<patientbirthdate>19470719</patientbirthdate>
			<patientonsetage>65</patientonsetage>
			<patientonsetageunit>801</patientonsetageunit>
			<patientagegroup>6</patientagegroup>
			<patientweight>55</patientweight>
			<patientheight>167</patientheight>
			<patientsex>2</patientsex>
			<resultstestsprocedures>Unknown date -  Urine culture: Negative.
Proteinuria: 0.37g/24h
22/Nov/2012 - Chest X-ray: no signs to support the presence of Wegener's granulomatosis.</resultstestsprocedures>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Bladder cancer</patientepisodename>
				<patientmedicalstartdateformat>602</patientmedicalstartdateformat>
				<patientmedicalstartdate>2011</patientmedicalstartdate>
				<patientmedicalcontinue>1</patientmedicalcontinue>
				<patientmedicalcomment>Bricker urinary diversion</patientmedicalcomment>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Metastases to liver</patientepisodename>
				<patientmedicalcontinue>1</patientmedicalcontinue>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Metastases to lymph nodes</patientepisodename>
				<patientmedicalcontinue>1</patientmedicalcontinue>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Epistaxis</patientepisodename>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Bronchitis</patientepisodename>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Stomatitis</patientepisodename>
				<patientmedicalcontinue>1</patientmedicalcontinue>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Hypercholesterolaemia</patientepisodename>
				<patientmedicalcontinue>1</patientmedicalcontinue>
				<patientmedicalcomment>treated with Lescol</patientmedicalcomment>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Ex-tobacco user</patientepisodename>
				<patientmedicalcomment>10 cigarettes per day for 30 years until June 2010</patientmedicalcomment>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Breast cancer</patientepisodename>
				<patientmedicalstartdateformat>602</patientmedicalstartdateformat>
				<patientmedicalstartdate>1999</patientmedicalstartdate>
				<patientmedicalcontinue>1</patientmedicalcontinue>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Breast lump removal</patientepisodename>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Radiotherapy</patientepisodename>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Urinary cystectomy</patientepisodename>
				<patientmedicalstartdateformat>102</patientmedicalstartdateformat>
				<patientmedicalstartdate>20100825</patientmedicalstartdate>
				<patientmedicalcontinue>2</patientmedicalcontinue>
				<patientmedicalenddateformat>102</patientmedicalenddateformat>
				<patientmedicalenddate>20100825</patientmedicalenddate>
				<patientmedicalcomment>Cystectomy</patientmedicalcomment>
			</medicalhistoryepisode>
			<patientpastdrugtherapy>
				<patientdrugname>GEMZAR</patientdrugname>
				<patientdrugstartdateformat>610</patientdrugstartdateformat>
				<patientdrugstartdate>201010</patientdrugstartdate>
				<patientdrugenddateformat>610</patientdrugenddateformat>
				<patientdrugenddate>201101</patientdrugenddate>
				<patientindicationmeddraversion>15.1</patientindicationmeddraversion>
				<patientdrugindication>Bladder cancer</patientdrugindication>
			</patientpastdrugtherapy>
			<patientpastdrugtherapy>
				<patientdrugname>CISPLATINE</patientdrugname>
				<patientdrugstartdateformat>610</patientdrugstartdateformat>
				<patientdrugstartdate>201010</patientdrugstartdate>
				<patientdrugenddateformat>610</patientdrugenddateformat>
				<patientdrugenddate>201101</patientdrugenddate>
				<patientindicationmeddraversion>15.1</patientindicationmeddraversion>
				<patientdrugindication>Bladder cancer</patientdrugindication>
			</patientpastdrugtherapy>
			<reaction>
				<primarysourcereaction>Purpura cutane</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Purpura</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Purpura</reactionmeddrapt>
				<termhighlighted>3</termhighlighted>
				<reactionstartdateformat>102</reactionstartdateformat>
				<reactionstartdate>20121122</reactionstartdate>
				<reactionenddateformat>102</reactionenddateformat>
				<reactionenddate>20121214</reactionenddate>
				<reactionduration>22</reactionduration>
				<reactiondurationunit>804</reactiondurationunit>
				<reactionfirsttime>15</reactionfirsttime>
				<reactionfirsttimeunit>804</reactionfirsttimeunit>
				<reactionlasttime>13</reactionlasttime>
				<reactionlasttimeunit>804</reactionlasttimeunit>
				<reactionoutcome>6</reactionoutcome>
			</reaction>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20121122</testdate>
				<testname>Alanine aminotransferase</testname>
				<testresult>13</testresult>
				<testunit>IU/l</testunit>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20121130</testdate>
				<testname>Alanine aminotransferase</testname>
				<testresult>10</testresult>
				<testunit>IU/l</testunit>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20121122</testdate>
				<testname>Aspartate aminotransferase</testname>
				<testresult>10</testresult>
				<testunit>IU/l</testunit>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20121130</testdate>
				<testname>Aspartate aminotransferase</testname>
				<testresult>20</testresult>
				<testunit>IU/l</testunit>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20121123</testdate>
				<testname>Biopsy</testname>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20121122</testdate>
				<testname>Albumin</testname>
				<testresult>35</testresult>
				<testunit>g/l</testunit>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20121130</testdate>
				<testname>Albumin</testname>
				<testresult>37</testresult>
				<testunit>g/l</testunit>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20121122</testdate>
				<testname>Alkaline phosphatase</testname>
				<testresult>94</testresult>
				<testunit>IU/l</testunit>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20121130</testdate>
				<testname>Alkaline phosphatase</testname>
				<testresult>71</testresult>
				<testunit>IU/l</testunit>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20121122</testdate>
				<testname>Bilirubin</testname>
				<testresult>4</testresult>
				<testunit>&#xc2b5;mol/l</testunit>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20121130</testdate>
				<testname>Bilirubin</testname>
				<testresult>8</testresult>
				<testunit>&#xc2b5;mol/l</testunit>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20121122</testdate>
				<testname>Calcium</testname>
				<testresult>2.22</testresult>
				<testunit>mmol/l</testunit>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20121130</testdate>
				<testname>Calcium</testname>
				<testresult>2.33</testresult>
				<testunit>mmol/l</testunit>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testname>Creatinine</testname>
				<testresult>52</testresult>
				<testunit>&#xc2b5;mol/l</testunit>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20121122</testdate>
				<testname>Creatinine</testname>
				<testresult>83</testresult>
				<testunit>&#xc2b5;mol/l</testunit>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20121130</testdate>
				<testname>Creatinine</testname>
				<testresult>82</testresult>
				<testunit>&#xc2b5;mol/l</testunit>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20121122</testdate>
				<testname>Folate</testname>
				<testresult>8.6</testresult>
				<testunit>mmol/l</testunit>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20121122</testdate>
				<testname>Iron</testname>
				<testresult>12.2</testresult>
				<testunit>&#xc2b5;mol/l</testunit>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20121122</testdate>
				<testname>LDH</testname>
				<testresult>180</testresult>
				<testunit>IU/l</testunit>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20121130</testdate>
				<testname>LDH</testname>
				<testresult>168</testresult>
				<testunit>IU/l</testunit>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20121122</testdate>
				<testname>Potassium</testname>
				<testresult>3.9</testresult>
				<testunit>mmol/l</testunit>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20121130</testdate>
				<testname>Potassium</testname>
				<testresult>4.7</testresult>
				<testunit>mmol/l</testunit>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20121122</testdate>
				<testname>Sodium</testname>
				<testresult>134</testresult>
				<testunit>mmol/l</testunit>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20121130</testdate>
				<testname>Sodium</testname>
				<testresult>138</testresult>
				<testunit>mmol/l</testunit>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20121122</testdate>
				<testname>Urea</testname>
				<testresult>3.7</testresult>
				<testunit>mmol/l</testunit>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20121130</testdate>
				<testname>Urea</testname>
				<testresult>5.2</testresult>
				<testunit>mmol/l</testunit>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testname>Chest X-ray</testname>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testname>Urine culture</testname>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20121122</testdate>
				<testname>GGT</testname>
				<testresult>30</testresult>
				<testunit>IU/l</testunit>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20121130</testdate>
				<testname>GGT</testname>
				<testresult>17</testresult>
				<testunit>IU/l</testunit>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20121122</testdate>
				<testname>Hemoglobin</testname>
				<testresult>9.1</testresult>
				<testunit>g/dL</testunit>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20121130</testdate>
				<testname>Hemoglobin</testname>
				<testresult>10.1</testresult>
				<testunit>g/dL</testunit>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20121122</testdate>
				<testname>Platelet count</testname>
				<testresult>251000</testresult>
				<testunit>/mm^3</testunit>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20121130</testdate>
				<testname>Platelet count</testname>
				<testresult>431000</testresult>
				<testunit>/mm^3</testunit>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20121122</testdate>
				<testname>Protein</testname>
				<testresult>69</testresult>
				<testunit>g/l</testunit>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20121130</testdate>
				<testname>Protein</testname>
				<testresult>69</testresult>
				<testunit>g/l</testunit>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20121122</testdate>
				<testname>Serum ferritin</testname>
				<testresult>553</testresult>
				<testunit>ng/mL</testunit>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20121122</testdate>
				<testname>Transferrin</testname>
				<testresult>16.7</testresult>
				<testunit>%</testunit>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20121122</testdate>
				<testname>Vitamin B12</testname>
				<testresult>2440</testresult>
				<testunit>pmol/L</testunit>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20121122</testdate>
				<testname>Leukocyte count NOS</testname>
				<testresult>17800</testresult>
				<testunit>/mm^3</testunit>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20121130</testdate>
				<testname>Leukocyte count NOS</testname>
				<testresult>9200</testresult>
				<testunit>/mm^3</testunit>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20121122</testdate>
				<testname>Polymorphonuclear count</testname>
				<testresult>14000</testresult>
				<testunit>/mm^3</testunit>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20121130</testdate>
				<testname>Polymorphonuclear count</testname>
				<testresult>8500</testresult>
				<testunit>/mm^3</testunit>
				<moreinformation>2</moreinformation>
			</test>
			<drug>
				<drugcharacterization>1</drugcharacterization>
				<medicinalproduct>panitumumab</medicinalproduct>
				<obtaindrugcountry>FR</obtaindrugcountry>
				<drugauthorizationnumb>125-147</drugauthorizationnumb>
				<drugauthorizationcountry>US</drugauthorizationcountry>
				<drugauthorizationholder>Amgen</drugauthorizationholder>
				<drugstructuredosagenumb>300</drugstructuredosagenumb>
				<drugstructuredosageunit>003</drugstructuredosageunit>
				<drugdosagetext>300 mg, UNK</drugdosagetext>
				<drugdosageform>Solution for injection</drugdosageform>
				<drugadministrationroute>042</drugadministrationroute>
				<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
				<drugindication>Transitional cell carcinoma</drugindication>
				<drugstartdateformat>102</drugstartdateformat>
				<drugstartdate>20121107</drugstartdate>
				<drugstartperiod>15</drugstartperiod>
				<drugstartperiodunit>804</drugstartperiodunit>
				<druglastperiod>13</druglastperiod>
				<druglastperiodunit>804</druglastperiodunit>
				<drugenddateformat>102</drugenddateformat>
				<drugenddate>20121109</drugenddate>
				<drugtreatmentduration>3</drugtreatmentduration>
				<drugtreatmentdurationunit>804</drugtreatmentdurationunit>
				<actiondrug>1</actiondrug>
				<activesubstance>
					<activesubstancename>panitumumab</activesubstancename>
				</activesubstance>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Purpura</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugresult>Yes</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Purpura</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugresult>Yes</drugresult>
				</drugreactionrelatedness>
			</drug>
			<drug>
				<drugcharacterization>2</drugcharacterization>
				<medicinalproduct>METHOTREXATE</medicinalproduct>
				<drugstructuredosagenumb>46</drugstructuredosagenumb>
				<drugstructuredosageunit>003</drugstructuredosageunit>
				<drugdosagetext>46 mg, UNK</drugdosagetext>
				<drugadministrationroute>042</drugadministrationroute>
				<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
				<drugindication>Transitional cell carcinoma</drugindication>
				<drugstartdateformat>102</drugstartdateformat>
				<drugstartdate>20120926</drugstartdate>
				<drugstartperiod>57</drugstartperiod>
				<drugstartperiodunit>804</drugstartperiodunit>
				<activesubstance>
					<activesubstancename>METHOTREXATE</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization>2</drugcharacterization>
				<medicinalproduct>VELBE</medicinalproduct>
				<drugstructuredosagenumb>4.6</drugstructuredosagenumb>
				<drugstructuredosageunit>003</drugstructuredosageunit>
				<drugdosagetext>4.6 mg, UNK</drugdosagetext>
				<drugadministrationroute>042</drugadministrationroute>
				<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
				<drugindication>Transitional cell carcinoma</drugindication>
				<drugstartdateformat>102</drugstartdateformat>
				<drugstartdate>20121107</drugstartdate>
				<drugstartperiod>15</drugstartperiod>
				<drugstartperiodunit>804</drugstartperiodunit>
				<druglastperiod>13</druglastperiod>
				<druglastperiodunit>804</druglastperiodunit>
				<drugenddateformat>102</drugenddateformat>
				<drugenddate>20121109</drugenddate>
				<drugtreatmentduration>3</drugtreatmentduration>
				<drugtreatmentdurationunit>804</drugtreatmentdurationunit>
				<activesubstance>
					<activesubstancename>VINBLASTINE SULFATE</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization>2</drugcharacterization>
				<medicinalproduct>ADRIAMYCIN</medicinalproduct>
				<drugstructuredosagenumb>46</drugstructuredosagenumb>
				<drugstructuredosageunit>003</drugstructuredosageunit>
				<drugdosagetext>46 mg, UNK</drugdosagetext>
				<drugadministrationroute>042</drugadministrationroute>
				<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
				<drugindication>Transitional cell carcinoma</drugindication>
				<drugstartdateformat>102</drugstartdateformat>
				<drugstartdate>20121107</drugstartdate>
				<drugstartperiod>15</drugstartperiod>
				<drugstartperiodunit>804</drugstartperiodunit>
				<druglastperiod>13</druglastperiod>
				<druglastperiodunit>804</druglastperiodunit>
				<drugenddateformat>102</drugenddateformat>
				<drugenddate>20121109</drugenddate>
				<drugtreatmentduration>3</drugtreatmentduration>
				<drugtreatmentdurationunit>804</drugtreatmentdurationunit>
				<activesubstance>
					<activesubstancename>DOXORUBICIN</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization>2</drugcharacterization>
				<medicinalproduct>CISPLATIN</medicinalproduct>
				<drugstructuredosagenumb>110</drugstructuredosagenumb>
				<drugstructuredosageunit>003</drugstructuredosageunit>
				<drugdosagetext>110 mg, UNK</drugdosagetext>
				<drugadministrationroute>042</drugadministrationroute>
				<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
				<drugindication>Transitional cell carcinoma</drugindication>
				<drugstartdateformat>102</drugstartdateformat>
				<drugstartdate>20121106</drugstartdate>
				<drugstartperiod>16</drugstartperiod>
				<drugstartperiodunit>804</drugstartperiodunit>
				<druglastperiod>13</druglastperiod>
				<druglastperiodunit>804</druglastperiodunit>
				<drugenddateformat>102</drugenddateformat>
				<drugenddate>20121109</drugenddate>
				<drugtreatmentduration>4</drugtreatmentduration>
				<drugtreatmentdurationunit>804</drugtreatmentdurationunit>
				<activesubstance>
					<activesubstancename>CISPLATIN</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization>2</drugcharacterization>
				<medicinalproduct>LESCOL</medicinalproduct>
				<drugseparatedosagenumb>1</drugseparatedosagenumb>
				<drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
				<drugintervaldosagedefinition>804</drugintervaldosagedefinition>
				<drugdosagetext>UNK</drugdosagetext>
				<activesubstance>
					<activesubstancename>FLUVASTATIN SODIUM</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization>2</drugcharacterization>
				<medicinalproduct>ANTIINFECTIVES AND ANTISEPTICS FOR LOCAL ORAL</medicinalproduct>
			</drug>
			<summary>
				<narrativeincludeclinical>The following event was received from an Investigator Sponsored Study (ISS)

This 65 year old female was participating in an intensified methotrexate, vinblastine, doxorubicin and cisplatin (I-MVAC) with or without panitumumab as first-line treatment of advanced urothelial carcinoma in patients without H-Ras or K-Ras mutations randomized phase III study and developed purpura cutane.

The subject's medical history included bladder carcinoma diagnosed in 2011 with metastases to liver and lymph nodes, Bricker urinary diversion, episodes of epistaxis, bronchitis, oral mucositis, hypercholesterolemia, smoking (10 cigarettes per day for 30 years until June 2010), and breast cancer treated with lumpectomy and radiotherapy (no supplement hormone or chemotherapy). The subject did not have relevant family history. Previous treatment for the condition under study included an unspecified surgery and chemotherapy. Concomitant medications included Lescol (fluvastatin sodium) and "mouthwash".

The subject received the first dose of panitumumab in combination with methotrexate, Velbe (vinblastine), Adriamycin (doxorubicin) and cisplatin on 06/Nov/2012. Approximately two weeks later, on 22/Nov/2012, the subject was hospitalized to receive the fifth course of study chemotherapy. Reportedly, between cycles the subject had developed grade I asthenia for seven days, grade I vomiting, prolonged grade III mucositis with significant ulceration for 10 days, slight response to Triflucan (fluconazole) and a non-recurrent episode of hematuria on 18/Nov/2012 apparently synchronous with the onset of purpura on the legs. The subject did not develop nausea, gastrointestinal toxicity, hematological toxicity, paresthesia, ototoxicity or pain. A urine culture was negative. Reportedly, the subject who had a Bricker urinary diversion had presented an episode of hematuria associated with infiltrated purpura. Previous platelet counts from last month and at the day of examination did not revealed thrombocytopenia. The subject also had history of episodes of epistaxis for two weeks and bronchitis for two months.

On admission, physical examination revealed grade II oral mucositis with sores, scabs and microvesicles on the lips, petechiae of the soft palate and lesions suggestive of either healing mucositis or oral lichen planus and infiltrated purpura on the front of her legs. No other skin lesions, particularly no folliculitis associated with panitumumab were found. The subject remained afebrile. Additional physical examination was normal. The subject's general state of health was good. Laboratory tests revealed leukocyte count of 17800/mm3, polymorphonuclear count of 14000/mm3, hemoglobin of 9.1 g/dL, platelet count of 251000/mm3, creatinine of 83 umol/L, urea at 3.7 mmol/L, sodium of 134 mmol/L, potassium of 3.9 mmol/L, calcium at 2.22 mmol/L, protein of 69 g/L, alkaline phosphatase of 94 IU/L, aspartate aminotransferase of 10 IU/L, alanine aminotransferase of 13 IU/L, and gamma glutamyltransferase of 30 IU/L, total bilirubin of 4 umol/l, lactate dehydrogenase of 180 IU/L, albumin of 35 g/L, iron of 12.2 umol/l, ferritin of 553 ng/mL, folates of 8.6 mmol/L, vitamin B12 at 2440 pmol/l, and transferring saturation coefficient of 16.7%. There was improvement in renal function after hydration (creatinine of 52 umol/L) and 24-h proteinuria was 0.37 g/24 h. The latest chest x-ray performed showed no signs to support the presence of Wegener's granulomatosis.

The investigator's assessment was probable vascular purpura, however certain criteria suggested thrombocytopenia. Biopsy with histology and IF, screens for infectious and autoimmune diseases and measures of vitamin C concentrations would be performed to eliminate scurvy. Vitamin C supplementation was suggested. The dermatologists opinion was probable microvascularity. On 23/Nov/2012, skin biopsy was done however result were not provided at the time of this report. Immunological screen was requested with assay of anti-neutrophil cytoplasmic antibody (ANCA), anti-streptolysin O (ASLO), anti-nuclear antibodies, anti-DNA antibodies, cryoglobulinaemia, C3, C4, CHso, rheumatoid factor, antinuclear factor as well as hepatitis B and C.

The subject was discharged from the hospital on 26/Nov/2012. The event was reported as ongoing at the time of discharge. Treatment at discharge for various symptoms causing discomfort included Lescol (fluvastatin sodium), Triflucan (fluconazole) and Fortimel (proteins) and Zovirax (aciclovir) for probable herpetic stomatitis.

Four days later, on 30/Nov/2012, the subject was re-hospitalized for the fifth course of study chemotherapy. Physical examination revealed grade I oral mucositis and purpura on the front of both legs which was less infiltrated compared to the examination on 22/Nov/2012. Laboratory tests revealed leukocyte count of 9200/mm3, polymorphonuclear count of 8500/mm3, hemoglobin of 10.1 g/dL, platelet count of 431000/mm3, creatinine of 82 umol/L, urea at 5.2 mmol/L, sodium of 138 mmol/L, potassium of 4.7 mmol/L, calcium at 2.33 mmol/L, protein of 69 g/L, alkaline phosphatase of 71 IU/L, aspartate aminotransferase of 20 IU/L, alanine aminotransferase of 10 IU/L, and gamma glutamyltransferase of 17 IU/L, total bilirubin of 8 umol/l, lactate dehydrogenase of 168 IU/L and albumin of 37 g/L. The following day, on 01/Dec/2012, the subject received the next dose of methotrexate, Velve, Adriamycin and cisplatin after being postponed one week. Panitumumab was not administered due to the persistence of purpura on the legs. Additional treatment included Emend (aprepitant), Solupred (prednisolone) and Primperan (metoclopramide hydrochloride). The following day, on 02/Dec/2012 the subject was discharged from the hospital. The event was reported as ongoing at the time of this report. The subject would be readmitted on 14/Dec/2012 as stated by the investigator. Associated co morbidity included insertion and maintenance of infusion pump and adjustment and maintenance of CVC or catheter vascular device. The subject's last dose of panitumumab in combination with methotrexate, vinblastine, doxorubicin and cisplatin prior to the event was on 07/Nov/2012. Panitumumab was temporarily withheld.

The investigator reported that there was a reasonable possibility that the event was related to panitumumab.

ADDITIONAL INFORMATION RECEIVED ON 02/JAN/2013: Previous treatment for the condition under study included cystectomy on 25/Aug/2010 and four cycles of adjuvant chemotherapy with Gemzar (gemcitabine) from October 2010 to January 2011. Previous and ongoing treatment included cisplatin. The date when subject received the first dose of panitumumab in combination with Velbe, Adriamycin and cisplatin was updated to 07/Nov/2012. The investigator reported that purpura cutane was grade 2. The results of biopsy with histology and IF, screens for infectious and autoimmune diseases and measures of vitamin C concentrations were not available. Additionally, results of immunological screen with assay of anti-neutrophil cytoplasmic antibody (ANCA), anti-streptolysin O (ASLO), anti-nuclear antibodies, anti-DNA antibodies, cryoglobulinaemia, C3, C4, CHso, rheumatoid factor, antinuclear factor and hepatitis B and C were also not available. The outcome of the event purpura cutane remained as resolving. The etiology of the event purpura cutane was not identified. The subject's last dose of investigational product prior to the event was administered during cycle 4 between 07/Nov/2012 and 09/Nov/2012. Panitumumab was permanently discontinued at cycle 5.

ADDITIONAL INFORMATION RECEIVED ON 23/Jan/2013: The investigator stated that the subject received methotrexate prior to the onset of the event on 26/Sep/2012, 11/Oct/2012, 25/Oct/2012 and 07/Nov/2012 and during the event on 01/Dec/2012 and 15/Dec/2012. The end date of the event was reported as 14/Dec/2012, however, the outcome was not provided.</narrativeincludeclinical>
				<sendercomment>Panitumumab is a high-affinity fully human immunoglobulin IgG2 monoclonal antibody that targets the human epidermal growth factor receptor leading to inhibition of EGFr activation.

The event purpura has not been documented as listed or expected in the Amgen Development Core Safety Information for product panitumumab.

Although a temporal association exists, it is not sufficient to establish, or rule out, a causal relationship between study drug and the event reported in this case. Causality is confounded by concurrent methotrexate, vinblastine, doxorubicin and cisplatin administration.

This individual case report does not change the safety profile of the product.</sendercomment>
			</summary>
		</patient>
	</safetyreport>
</ichicsr>
